Jennifer Kim MD
Differentiate between traditional positive airway pressure (PAP) therapies and emerging alternative treatments, such as hypoglossal nerve stimulation and novel pharmacotherapies.
Appraise the role of hypoglossal nerve stimulation (such as Inspire therapy) from a non-surgical management perspective, focusing on candidate selection, device titration, and long-term clinical outcomes.
Evaluate the impact of dual GIP and GLP-1 receptor agonists (such as tirzepatide/Zepbound) on obstructive sleep apnea severity and determine how to integrate these pharmacotherapies into a metabolic-focused treatment plan.
Analyze emerging clinical evidence linking untreated obstructive sleep apnea to systemic pathophysiological pathways that potentially increase the risk for neurodegenerative conditions, specifically Alzheimer’s disease.